There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), UnitedHealth (UNH – Research Report) and Haleon PLC Sponsored ADR (HLN – Research Report) with bullish sentiments.
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $200.00. The company’s shares closed last Monday at $94.30.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioMarin Pharmaceutical with a $122.56 average price target, a 29.0% upside from current levels. In a report issued on February 28, Morgan Stanley also maintained a Buy rating on the stock with a $131.00 price target.
See the top stocks recommended by analysts >>
UnitedHealth (UNH)
Bank of America Securities analyst Kevin Fischbeck maintained a Buy rating on UnitedHealth today and set a price target of $650.00. The company’s shares closed last Monday at $480.78.
According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $599.33, a 24.5% upside from current levels. In a report issued on February 28, Stephens also reiterated a Buy rating on the stock with a $605.00 price target.
Haleon PLC Sponsored ADR (HLN)
Bank of America Securities analyst Graham Parry reiterated a Buy rating on Haleon PLC Sponsored ADR today and set a price target of p344.00. The company’s shares closed last Monday at $7.85.
According to TipRanks.com, Parry is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Haleon PLC Sponsored ADR with a $4.66 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMRN:
- BioMarin price target raised to $118 from $114 at Stifel
- BioMarin price target lowered to $74 from $83 at Wedbush
- BioMarin price target lowered to $112 from $119 at Canaccord
- BioMarin price target raised to $127 from $110 at Credit Suisse
- BioMarin sees FY23 EPS under new method of $1.80-$2.05, consensus $1.61
